Mirador Therapeutics is a biotech company that leverages cutting-edge science and technology to develop novel treatments for a spectrum of diseases. From oncology to neurodegenerative disorders, the company’s research spans a broad range of therapeutic areas, reflecting its commitment to tackling diseases that afflict millions worldwide.
Mirador Therapeutics has raised $400 million in a Series A round. The new round was led by led by ARCH Venture Partners, with early investments from OrbiMed and Fairmount. Other premier life sciences investors also participated, including Fidelity Management & Research Company, Point72, Farallon Capital Management, Boxer Capital, TCGX, Invus, Logos Capital, Moore Strategic Ventures, Blue Owl Healthcare Opportunities, Sanofi Ventures, Woodline Partners LP, Venrock Healthcare Capital Partners, RTW Investments, and Alexandria Venture Investments.
Mirador Therapeutics, San Diego, California, United States, was founded by Mark McKenna. “At Mirador, we envision a bold new era of precision medicine for immune-mediated inflammatory and fibrotic diseases driven by speed and superior development accuracy. The industry has only scratched the surface of utilizing advances in human genetics – coupled with exponential progress in machine learning – to accelerate the development of precision therapies for patients who need them the most. With a proven team, distinguished board of directors, leading healthcare investors and proprietary data-driven approach, we aim to create a leading precision medicine company at scale to provide important new treatment options for patients,” noted Mark McKenna, chairman and CEO of Mirador.
